Clinical Trial Update: Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and efficacy of MIM-D3 ophthalmic solution for dry eye has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Eye

Drugs mentioned

• MIM-D3

Snippet

Sponsor: Mimetogen Pharmaceuticals USA, Inc. | Conditions: Dry Eye | Phase 2 | Status: COMPLETED